Today, we are on site for day 3 of ISPOR 2019 annual meeting in New Orleans, Louisiana!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Yousuf Zafar, MD, associate professor of medicine and population health sciences at Duke University School of Medicine and a medical oncologist at Duke Cancer Institute, and Lou Garrison, PhD, a professor emeritus in the Department of Pharmacy at University of Washington.

The third day of the conference covered several hot topics that require innovative ways of thinking about healthcare. First, there was a session on biosimilars and addressing the legal, regulatory, and coverage challenges. There was also a session that explored how meaningful models can be constructed for rare conditions. Finally, there was a session on the affordability of prescription drugs with high price tags continue to enter the market.

Read coverage and watch additional interviews from the meeting at AJMC.com.

That’s all from the ISPOR 2019 annual meeting. Thank you for watching 

Videos

Interviews with Yousuf Zafar, MD, of Duke Cancer Institute, and Lou Garrison, PhD, of University of Washington, from day 3 of the ISPOR 2019 annual meeting in New Orleans, Louisiana. You can now watch day 1 and day 2.

ISPOR 2019: On Location Interviews, Day 3

Today, we are on site for day 2 of ISPOR’s annual conference in New Orleans!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Julia Slejko, PhD, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, about incorporating the patient voice into value-based decision making, and Michael Sherman, MD, the chief medical officer of Harvard Pilgrim Health Care, about ICER’s value-based price assessments.

During the second day of the meeting, sessions surrounded value and different mechanisms of determining cost-effectiveness. First, there was a session on ICER and its value-based price assessments that inform payer access decisions. Another session took a look at different approaches that leverage real-world data in order to extend the survival curve in cost-effectiveness analyses. Finally, a session explored additional elements of value that could be included in value assessment of new drugs.

That’s all for today. Stay tuned for tomorrow’s 

 On Location, where we will sit down with Yousuf Zafar, MD, associate professor of medicine and population health sciences at Duke University School of Medicine and a medical oncologist at Duke Cancer Institute, about incorporating patient-reported process measures in value-based programs, and Lou Garrison, PhD, a professor emeritus in the Department of Pharmacy at University of Washington, about the benefits and challenges of using the quality-adjusted life year to determine cost-effectiveness.

Interviews with Julia Slejko, PhD, of the University of Maryland School of Pharmacy, and Michael Sherman, MD, of Harvard Pilgrim Health Care, from day 2 of the ISPOR 2019 annual meeting in New Orleans, Louisiana.

ISPOR 2019: On Location Interviews, Day 2

Today, we are on site in New Orleans, Louisiana, at ISPOR’s annual meeting.

We will be recapping some of the top news presented each day at the conference—and soon, we’ll speak with Joey Mattingly, PharmD, MBA, assistant professor of Pharmacy Practice and Science at the University of Maryland School of Pharmacy, and Robert Dubois, MD, PhD, chief science officer and executive vice president of the National Pharmaceutical Council, about different developments in health economics and outcomes research.

The meeting kicked off today with discussions surrounding innovative ways to deliver healthcare and debates over measures of value, beginning with a session that took a deep dive into how innovative technologies will require innovative ways of thinking about healthcare. There was also a session on global developments in artificial intelligence and machine learning in healthcare, which looked at different challenges and opportunities posed by these developments. Finally, a panel weighed the arguments for and against the use of the quality-adjusted life years for determining the health effects of medical interventions.

 On Location, where we will sit down with Julia Slejko, PhD, an assistant professor of pharmaceutical health services research at the University of Maryland School of Pharmacy, about incorporating the patient voice into value-based decision making, and Michael Sherman, MD, the chief medical officer of Harvard Pilgrim Health Care, about ICER’s value-based price assessments.

Interviews with Joey Mattingly, PharmD, MBA, of the University of Maryland School of Pharmacy, and Robert Dubois, MD, PhD, of the National Pharmaceutical Council from day 1 of the ISPOR 2019 annual meeting in New Orleans, Louisiana.

ISPOR 2019: On Location Interviews, Day 1

Today, we are on site for day 2 of the Community Oncology Alliance’s annual Community Oncology Conference in Orlando, Florida!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Debra Patt, MD, vice president of Texas Oncology, and Jeff Vacirca, MD, of New York Cancer & Blood Specialists.

The second day of the meeting focused on cancer drugs and different strategies for addressing their cost. There was a session on chimeric antigen receptor T-cell therapy, which explored different clinical and reimbursement challenges associated with the treatment. In addition, there were sessions on the adverse impact pharmacy benefit managers have on cancer care, and the effect of step therapy and utilization management on access to cancer treatments. We also got an industry perspective on price, cost, and value of cancer drugs.

Read coverage and watch additional interviews

That’s all from COA's Annual Community Oncology Conference. Join us again May 19-21, when we will be reporting on site at The International Society for Pharmacoeconomics and Outcomes Research’s annual meeting being held in New Orleans, Louisiana.

On day 2 of the Community Oncology Alliance's annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Debra Patt, MD, MPH, MBA, executive vice president of Texas Oncology, and Jeffrey Vacirca, MD, chief executive officer of New York Cancer & Blood Specialists.

COA 2019: On Location Interviews, Day 2

Today, we are on site in Orlando, Florida, at the Community Oncology Alliance (COA)’s annual Community Oncology Conference!

We will be recapping some of the top news presented each day during the conference—and soon, we’ll speak with Sibel Blau, MD, Northwest Medical Specialties, and Ted Okon, the executive director of COA, about different trends and policies impacting oncologists and their patients.

With the theme of “Ensuring Quality, Affordable & Accessible Cancer Care,” the meeting kicked off today with a look at how cancer care delivery is transforming, with sessions focused on the evolution of payment models and the impact of different healthcare policies. The future of cancer care was on display, first with a session on artificial intelligence in community oncology. There was also a session highlighting COA’s Oncology Care Model (OCM) 2.0, a proposed model that builds on CMS’ OCM. Finally, a session in the patient advocacy track looked at how community oncology is shaping the future of cancer care by bringing clinical trials into the community setting.

Read coverage and watch additional interviews from the meeting

, where we will sit down with Debra Patt of Texas Oncology about artificial intelligence and clinically integrated networks, and Jeff Vacirca, MD, of New York Cancer & Blood Specialists about challenges facing community oncologists and how OneOncology is addressing those challenges.

On day 1 of the Community Oncology Alliance (COA)'s annual Community Oncology Conference, held April 4-5 in Orlando, Florida, we spoke with Ted Okon, executive director of COA, and Sibel Blau, MD, medical director of Northwest Medical Specialties, PLLC.

COA 2019: On Location Interviews, Day 1

We are on site in Washington, DC, for day 2 of the Association of Community Cancer Centers’ Annual Meeting and Cancer Center Business Summit!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with James Hamrick, MD, senior medical director of Flatiron Health, and Ali McBride, PharmD, MS, BCPS, BCOP, incoming president of ACCC.

The second day of the meeting focused on technology in healthcare and the digital health revolution. There was a session on likely innovations in health IT over the next 18 years based on insights from leaders in government, academia, and industry. In addition, there was a panel discussion on how wearables are generating patient-reported outcomes and empowering providers to be able to better manage symptoms and improve resource utilization.

Read about these stories and watch additional interviews from the meeting at AJMC.com.

That’s all from the ACCC Annual Meeting and Cancer Center Business Summit. Join us again April 4-5, when we will be reporting on site at the Community Oncology Alliance’s Community Oncology Conference being held in Orlando, Florida.

On day 2 of the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, we spoke with Ali McBride, PharmD, MS, BCPS, BCOP, clinical coordinator of hematology/oncology in the Department of Pharmacy at The University of Arizona Cancer Center, and James Hamrick, MD, senior medical director at Flatiron Health.

ACCC 2019: On Location Interviews, Day 2

We are on site in Washington, DC, at the Association of Community Cancer Centers’ Annual Meeting and Cancer Center Business Summit!

We will be recapping some of the top news presented each day during the meeting—and soon we’ll speak with Tom Gallo, the outgoing president of ACCC on trends in oncology care and preparing for the future, and Nicole Braccio, PharmD, of the National Patient Advocate Foundation on shared decision making and other conversations with patients.

The meeting kicked off with a look into the future, with sessions that analyzed how physicians, nurses and administrators will adapt over the next 10 years as cancer practices grapple with business, quality, and technology trends. There was also a session on federal policy shifts that impact care delivery, reimbursement, and patient access to care, as well as the government’s role in changing the healthcare landscape.

 On Location, where we will sit down with James Hamrick, MD, of Flatiron Health to discuss technology in care delivery, and Ali McBride, PharmD, to discuss biosimilars and more.

On day 1 of the Association of Community Cancer Centers (ACCC)'s 45th Annual Meeting & Cancer Center Business Summit, we spoke with Tom Gallo, the outgoing president of ACCC and Nicole Braccio, PharmD, director of policy at the National Patient Advocate Foundation.